Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 210

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 210
---
 have served as the Company’s auditor since 2021.

San Diego, California

March 6, 2025

 F-3

PART I—FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

REVELATION BIOSCIENCES, INC.

Consolidated Balance Sheets

    December 31,2024

    December 31,2023

    ASSETS

    Current assets:

    Cash and cash equivalents
     
    $
    6,499,018

    $
    11,991,701

    Deferred offering costs

    —

    71,133

    Prepaid expenses and other current assets

    66,699

    84,691

    Total current assets

    6,565,717

    12,147,525

    Property and equipment, net

    56,332

    65,084

    Total assets
     
    $
    6,622,049

    $
    12,212,609

    LIABILITIES AND STOCKHOLDERS’ EQUITY

    Current liabilities:

    Accounts payable
     
    $
    783,621

    $
    1,359,898

    Accrued expenses

    1,127,800

    1,152,460

    Deferred underwriting commissions

    —

    2,911,260

    Warrant liability

    2,246

    141,276

    Total current liabilities

    1,913,667

    5,564,894

    Total liabilities

    1,913,667

    5,564,894

    Commitments and Contingencies (Note 4)

    Stockholders’ equity:

    Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023 and 522,223 and 16,484 issued and outstanding at December 31, 2024 and December 31, 2023, respectively

    522

    16

    Additional paid-in-capital

    45,213,498

    32,114,801

    Accumulated deficit

    (40,505,638
    )

    (25,467,102
    )

    Total stockholders’ equity

    4,708,382